Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Low-grade Glioma Therapeutics Market Snapshot (2023 to 2033)

The global low-grade Glioma therapeutics market is expected to garner a market value of US$ 1038 Million in 2023 and is expected to accumulate a market value of US$ 1515.47 Million by registering a CAGR of 4.57% in the forecast period 2023-2033. Growth of the low-grade Glioma therapeutics market can be attributed to increasing prevalence of low-grade glioma and research and development to innovate medications. The market for low-grade Glioma therapeutics registered a CAGR of 3.4% in the historical period 2018 to 2022

Low-grade gliomas are a type of brain tumor that grow slowly and are often classified as Grade I or Grade II on the World Health Organization (WHO) grading scale. These types of tumors can be difficult to treat because they often infiltrate surrounding brain tissue and can be difficult to completely remove surgically.

Low-grade glioma therapeutics refers to the treatments used to manage low-grade gliomas, a type of slow-growing brain tumor. The goal of these treatments is to remove as much of the tumor as possible, prevent recurrence, and preserve normal brain function. The main therapeutic options include surgery, radiation therapy, and chemotherapy. The choice of treatment is personalized and depends on various factors such as the location and size of the tumor and the patient's overall health.

Report Attribute Details
Expected Market Value (2023) US$ 1038 Million
Anticipated Forecast Value (2033) US$ 1515.47 Million
Projected Growth Rate (2023 to 2033) 4.57% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Low-grade Glioma Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Low-grade Glioma therapeutics reflected a value of 3.4% during the historical period, 2018 to 2022.

Increased research and development activities in the field of low-grade glioma therapeutics have resulted in the development of new and improved treatments, further driving growth in the market. Moreover, increasing healthcare expenditure, driven by factors such as an aging population and increasing awareness of the need for effective treatments for low-grade gliomas, has also contributed to the growth of the market.

Thus, the market for Low-grade Glioma therapeutics is expected to register a CAGR of 4.57% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Low-grade Glioma Therapeutics Market?

New and effective medical technologies spurring growth of low-grade Glioma therapeutics

The incidence of brain tumors, including low-grade gliomas, is increasing globally, driving demand for effective treatments. There has been an increase in public and medical awareness of low-grade gliomas, which is leading to earlier diagnoses and more effective treatments. The development of new and more effective medical technologies for the diagnosis and treatment of low-grade gliomas is driving the growth of the market.

Increased healthcare expenditure globally, especially in developed countries, is driving the growth of the low-grade glioma therapeutics market as people are more willing to pay for effective treatments. The increasing focus on research and development of new treatments for low-grade gliomas is leading to the development of new and more effective therapies, driving market growth.

Availability of different treatments driving growth of Glimoa therapeutics

Surgery: The goal of surgical treatment is to remove as much of the tumor as possible while preserving normal brain function. In some cases, the entire tumor may be removed, but in many cases, only a portion can be safely removed.

Radiation therapy: Radiation therapy uses high-energy beams to destroy the tumor cells. This treatment is often used after surgery to help kill any remaining tumor cells and reduce the risk of recurrence.

Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. It is not commonly used to treat low-grade gliomas as these tumors are often resistant to chemotherapy.

Targeted therapy: Targeted therapy uses drugs to specifically target the cancer cells, rather than damaging normal cells. This type of therapy is still being studied for the treatment of low-grade gliomas, but it has shown promise in early clinical trials.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Low-grade Glioma Therapeutics Market?

Difficulty in diagnosing and expensive treatments creating obstacles for low-grade therapeutics market

The cost of treatments for low-grade gliomas is high, making them inaccessible to many patients, especially in developing countries. Currently, there are limited effective treatments for low-grade gliomas, and many of the available treatments come with significant side effects.

Low-grade gliomas can be difficult to diagnose, and the symptoms are often similar to those of other neurological conditions, making it difficult for physicians to make an accurate diagnosis. The underlying causes of low-grade gliomas are not well understood, making it difficult to develop new and effective treatments.

The low-grade glioma therapeutics market faces competition from alternative treatments, such as radiation therapy and chemotherapy, which are less invasive and less expensive.

Region-Wise Insights

Advances in Medical Technology Shaping Landscape for Low-grade Glioma Therapeutics Market in North America?

Research and development leading to innovation of medications for treating low-grade glioma therapeutics in North America

The North America low-grade glioma therapeutics market is one of the largest and most mature markets in the world. The market is driven by factors such as a high incidence of brain tumors, an aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure.

In North America, the United States is the largest market for low-grade glioma therapeutics, driven by factors such as a high incidence of brain tumors, a large and aging population, and a high level of healthcare expenditure. Canada is also a significant market for low-grade glioma therapeutics, driven by factors such as an aging population and increasing healthcare expenditure.

The North America low-grade glioma therapeutics market is dominated by major players such as Roche, Novartis, and Pfizer, who offer a range of treatments for low-grade gliomas, including chemotherapy, radiation therapy, and surgical treatments. The market is expected to continue to grow in the coming years, driven by advances in medical technology and increasing research and development activities in the field.

Overall, the North America low-grade glioma therapeutics market offers a significant opportunity for growth, driven by a large and aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure. Thus, North America is expected to possess 45% market share for low-grade glioma therapeutics market in 2023.

Presence of Key Players in Europe Creating Lucrative Opportunities for Low-grade Glioma Therapeutics Market in Europe?

Rising healthcare expenditure bolstering the market for low-grade glioma therapeutics

The Europe low-grade glioma therapeutics market offers a significant opportunity for growth, driven by a large and aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure. In Europe, the market is driven by a number of countries, including the United Kingdom, Germany, France, Italy, and Spain, which are among the largest markets for low-grade glioma therapeutics in the region.

The Europe low-grade glioma therapeutics market is dominated by major players such as Roche, Novartis, and Pfizer, who offer a range of treatments for low-grade gliomas, including chemotherapy, radiation therapy, and surgical treatments.

The market is expected to grow at a moderate pace in the coming years, driven by advances in medical technology and increasing research and development activities in the field. Thus, Europe is expected to possess 37% market share for low-grade glioma therapeutics market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Availability of Speciality Drugs Making Hospital Pharmacies Dependable?CTop of Form

Access to wider drugs making hospital pharmacies popular for low-grade glioma therapeutics

Hospital pharmacists have specialized training in managing and dispensing medications for patients with neurological conditions, including low-grade gliomas. This expertise can help ensure that patients receive the most appropriate and effective treatments for their condition. In addition, hospital pharmacies play a key role in coordinating care for patients with low-grade gliomas. Pharmacists can work with other healthcare providers, such as neurologists and oncologists, to ensure that patients receive the most appropriate and effective treatments for their condition.

Hospital pharmacies have access to a wider range of specialty drugs, including those used to treat low-grade gliomas. This can be especially important for patients with rare or complex conditions, who may require treatments that are not widely available.

Hospital pharmacists can monitor patients' treatments for low-grade gliomas, including monitoring for potential side effects and drug interactions. This can help ensure that patients receive the most effective and safe treatments for their condition. Thus, hospital pharmacies are expected to procure 40% market share for low-grade glioma therapeutics market in 2023.

Market Competition

Key players in the low-grade Glioma therapeutics market are Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly

  • Hoffmann-La Roche, a key player in the low-grade Glioma therapeutics market has undertaken extensive research to diagnose the nature of the ailment and innovate therapies to treat the same.
  • Incyte, another key player in the low-grade Glioma therapeutics market is focusing on getting its medication clinically tested to make it widely usable for patients suffering from the ailment.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1038 Million
Market Value in 2033 US$ 1515.47 Million
Growth Rate CAGR of 4.57% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023-2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa(MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of Middle East and Africa(MEA)
Key Companies Profiled
  • Day One Biopharmaceuticals
  • AnHeart Therapeutics
  • Beigene
  • SpringWorks Therapeutics
  • Servier
  • Helsinn
  • Forma Therapeutics
  • Hoffmann-La Roche
  • Incyte
  • Eli Lilly
Customization Available Upon Request

Key Segments Profiled in the Low-grade Glioma Therapeutics Industry Survey

Drug Class:

  • Trametinib
  • Dabrafenib
  • Ivosidenib
  • Mirdametinib

Route of Administration:

  • Topical
  • Oral

Distribution Channel:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa(MEA)

Frequently Asked Questions

How Big is the Low-grade Giloma Therapeutics Market?

The total market is estimated to accumulate US$ 1,038 million revenue in 2023.

What will be the Low-grade Giloma Therapeutics Market Growth Rate?

The global market is forecasted to grow at 4.57% CAGR through 2033.

What is the Predicted Low-grade Giloma Therapeutics Market Size for 2033?

The overall global market could reach a value of US$ 1,515.47 million by 2033.

What is the Contribution of North America in Global Low-grade Giloma Therapeutics Market?

North America market could contribute significantly with a 45% share in 2023.

Which is the Most Popular Low-grade Giloma Therapeutics Company?

AnHeart, Beigene, and Springworks are some popular companies in the global market.

Table of Content

1. Executive Summary | Low-Grade Glioma Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Trametinib

        5.3.2. Dabrafenib

        5.3.3. Ivosidenib

        5.3.4. Mirdametinib

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Topical

        6.3.2. Oral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Online Pharmacies

        7.3.2. Hospital Pharmacies

        7.3.3. Retail Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Day One Biopharmaceuticals

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. AnHeart Therapeutics

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Beigene

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. SpringWorks Therapeutics

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Servier

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Helsinn

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Forma Therapeutics

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Hoffmann-La Roche

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Incyte

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Eli Lilly

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033

Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Leukemia Therapeutics Treatment Market

Published : October 2023

Healthcare

Acrocallosal Syndrome Therapeutics Market

Published : January 2023

Healthcare

Bartonellosis Therapeutics Market

Published : January 2023

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Explore Healthcare Insights

View Reports

Low-Grade Glioma Therapeutics Market